论文部分内容阅读
Blood protein antigens and antibodies are recognised as promising biomarkers for early detection of cancers and their progression.Blood antigens seem more effective on detecting advanced stage cancers and their responses to treatment and predicting patient survival.The finding that patients with cancer produce antibodies against antigens in their tumors suggests that such antibodies could have diagnostic and prognostic values.Increased evidences demosntrate that blood antibodies have potentials in detecting early stage cancers even in their prediagnostic stages.Tumor-specific immunity of insulin-like growth factor binding protein-2 (IGFBP-2) has been reported in several cancers.We have recently found that IGFBP-2 antibodies can effectively detect early cancers, and in combination of serum IGFBP-2 antigen improve cancer diagnosis and potentially follow up cancer progression.Results in this field from different investigations will be presented and discussed.